Improving the Somatostatin Receptor Status Assessment for Personalized and Precise Management of Neuroendocrine Neoplasms with the Use of a 99m Tc-Radiolabeled Somatostatin Receptor Antagonist: The Final Results of the ERA PerMed TECANT Clinical Trial
This study aims to assess the safety and performance of a novel 99mTc-labeled somatostatin receptor antagonist in patients with neuroendocrine neoplasms.
Conducted a first-in-human injection of [99mTc]Tc-TECANT1 in ten patients with metastatic grade 1 or 2 neuroendocrine neoplasms.
Evaluated safety, pharmacokinetics, and dosimetry as primary endpoints.
Performed qualitative and quantitative comparison with 68Ga-SSTR PET for secondary endpoints.
[99mTc]Tc-TECANT1 was safe with a total body effective dose of 3.3 ± 0.7 mSv.
Superior diagnostic performance compared to SSTR PET was observed, with more detected lesions.
Achieved target-to-background contrast exceeding a factor of 2 for high-uptake lesions.
Cite This Study
Hubalewska-Dydejczyk et al. (2026) studied this question.